Literature DB >> 18448691

Detection of caspofungin resistance in Candida spp. by Etest.

Marie Desnos-Ollivier1, Françoise Dromer, Eric Dannaoui.   

Abstract

The caspofungin susceptibilities of 28 Candida sp. clinical isolates, including 8 caspofungin-resistant isolates characterized by mutations in the Fks1 protein, were determined by the Etest in RPMI and AM3 media. Good discrimination between wild-type and mutant isolates was obtained. These results suggest that the Etest is valuable for the detection of caspofungin resistance in Candida spp.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18448691      PMCID： PMC2446896          DOI： 10.1128/JCM.00053-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  26 in total

1.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Authors:  Jennifer Nielsen Kahn; Guillermo Garcia-Effron; Ming-Jo Hsu; Steven Park; Kieren A Marr; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

4.  Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.

Authors:  Sergey V Balashov; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

6.  Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

Authors:  Christopher D Miller; Ben W Lomaestro; Steven Park; David S Perlin
Journal:  Pharmacotherapy       Date:  2006-06       Impact factor: 4.705

7.  In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.

Authors:  Ralf Fleck; Annebärbel Dietz; Herbert Hof
Journal:  J Antimicrob Chemother       Date:  2007-02-09       Impact factor: 5.790

8.  Acquired resistance to echinocandins in Candida albicans: case report and review.

Authors:  Marie-Thérèse Baixench; Naji Aoun; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Stéphane Bretagne; Sandrine Ramires; Christophe Piketty; Eric Dannaoui
Journal:  J Antimicrob Chemother       Date:  2007-04-27       Impact factor: 5.790

9.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

Authors:  Mikkel Krogh-Madsen; Maiken Cavling Arendrup; Lars Heslet; Jenny Dahl Knudsen
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

10.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790
View more
  20 in total

1.  Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans.

Authors:  Catiana Dudiuk; Soledad Gamarra; Cristina Jimenez-Ortigosa; Florencia Leonardelli; Daiana Macedo; David S Perlin; Guillermo Garcia-Effron
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

2.  Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Authors:  Marie Desnos-Ollivier; Olivier Moquet; Taieb Chouaki; Anne-Marie Guérin; Françoise Dromer
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

3.  Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.

Authors:  Elodie Blanchard; Olivier Lortholary; Karine Boukris-Sitbon; Marie Desnos-Ollivier; Françoise Dromer; Didier Guillemot
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

4.  Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Cornelia Lass-Flörl; Alicia Gomez Lopez; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

5.  Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast.

Authors:  Cigdem Balkan; Ilkcan Ercan; Esin Isik; Esra Sahin Akdeniz; Orhan Balcioglu; Marie Kodedová; Olga Zimmermannová; Muhammed Dundar; Hana Sychrová; Ahmet Koc
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

6.  Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.

Authors:  Sandra A Asner; Stefano Giulieri; Manuel Diezi; Oscar Marchetti; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

7.  Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.

Authors:  Maiken Cavling Arendrup; Steven Park; Steven Brown; Michael Pfaller; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

8.  Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates.

Authors:  Ana Espinel-Ingroff; E Canton; J Peman; E Martín-Mazuelo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

9.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Dorothée Raoux; Damien Hoinard; Françoise Dromer; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.